Avoid for next 6-12 months until new structure has stabilised - Recensione dipendente - Dipendente anonimo presso IPSEN

1,0
28 dic 2017
Dipendente anonimo
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Excellent products with strong growth potential. Strong sales growth in past year Bold ambition of 1 new product or major indication launch per year from now on Strong new CEO

Svantaggi

Recent commercial restructure has been a car crash. Executed too quickly to meet management objectives rather than keeping the needs of employees involved at heart. Whole thing was poorly delivered and communicated and has resulted in low morale and some poor internal appointments when external hires would have been better for the business. Lack of,or poor processes which hinder agility. Sub-standard reward and recognition scheme and no consistency in recognition of a job well done

Esplora altre recensioni su IPSEN

5,0
17 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The recruiter that I worked with was wonderful and very in tuned with my career goals and the type of team I wanted to be a part of. He answered all of my questions in a timely manner and was transparent on which roles he felt would be a good match based on the leadership, team, and career aspirations.

Svantaggi

I did not have any cons related to my experience.

1,0
22 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

None, I cannot think of one pro.

Svantaggi

The worst experience in my 15 plus career in pharma. The managers are horrible, they work you to death and show zero appreciation. I was so thankful I was a temp, as I would never have wanted to be a full time after what I experienced. It's basically a hot mess of bullying by managers and the Sr. Director's have poor SVPs they report into so it makes sense they management style is horrid.

Vedi recensioni per: Utile|Valutazione|Data|Tutto